

PRIOR AUTHORIZATION REQUEST FORM

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) AGENTS

Kalydeco[®], Orkambi[®], Symdeko[®], Trikafta[™]

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Kalydeco[®] (ivacaftor), Orkambi[®] (lumacaftor/ivacaftor), Symdeko[®] (tezacaftor/ivacaftor and ivacaftor), Trikafta[™] (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have a documented diagnosis of cystic fibrosis (CF) as listed below? <ul style="list-style-type: none"> • Cystic fibrosis with pulmonary manifestations • Cystic fibrosis with other intestinal manifestations • Cystic fibrosis with other manifestations • Cystic fibrosis, unspecified 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the requesting provider a cystic fibrosis specialist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the provided documentation show that the member has a CF mutation that therequested medication is indicated to treat?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does the member demonstrate at least a 75% history of compliance with the Cystic Fibrosis Center clinic visits over the last 12 months? Documentation of adherence must be provided with the request.	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does the member demonstrate at least 80% adherence to prescribed medication therapies over the last 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

Adherence to prescribed medications will be verified by claim review and fill history, if available.			
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a continued medical need for therapy and has the therapy been effective and tolerable?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has member achieved a clinically significant response to therapy with documentation of at least ONE of the following? <ul style="list-style-type: none"> • Improvement or stabilization in lung function as demonstrated by a current FEV1 as compared to pre-treatment values. • Improvement or stabilization in Body Mass Index (BMI) as compared to pre-treatment BMI. • Member has a decrease in pulmonary exacerbations as demonstrated by a decrease in hospitalizations, emergency room visits and/or IV antibiotic use. 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Is member's ALT or AST not > 5 times the upper limit of normal (UNL) and ALT or AST is not > 3 times the UNL and bilirubin is not > 2 times the UNL?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does documentation show yearly ophthalmic examinations are performed to assess for possible non-congenital lens opacities for adolescent members between the ages of 12 – 18 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Did member demonstrate at least 80% adherence to prescribed medication therapies over at least the last 6 months prior to continuation of therapy requests? Adherence to prescribed medications will be verified by claim review and fill history.	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Is member followed at least annually by a practitioner who specializes in the care of patients with cystic fibrosis?	<input type="checkbox"/>	<input type="checkbox"/>	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 014
 Origination Date: 12/05/2019
 Reviewed/Revised Date: 01/27/2021
 Next Review Date: 01/27/2022
 Current Effective Date: 02/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.